Your session is about to expire
← Back to Search
Antibiotic
Microbiome Analysis for Rosacea
Phase < 1
Recruiting
Led By Anna Chien
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants must be over the age of 18 years old.
Participants must have the ability to understand and communicate with the investigator.
Must not have
Recently treated (4 weeks for topical antibiotics/steroids/other anti-inflammatory medications on the face, 8 weeks for systemic antibiotics/steroids/other immunosuppressive agents) or current (skin) diseases that would affect clinical evaluation and skin sampling.
Subjects with known bleeding disorders.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights
No Placebo-Only Group
Summary
This trial examines how different antimicrobial treatments affect the skin and gut bacteria in people with moderate to severe rosacea. It aims to see if these treatments can help by changing the bacteria that live on the skin and in the gut.
Who is the study for?
Adults over 18 with moderate-to-severe erythematotelangiectatic or papulopustular rosacea, or those without rosacea for control. Must understand the study and follow its rules. Can't join if they've had major GI surgery, bleeding disorders, recent facial treatments, certain drug use in past weeks, known allergies to trial medications, chronic diseases like diabetes or immunodeficiency, excessive scarring tendencies, are pregnant or have significant hair growth affecting evaluation.
What is being tested?
The trial is studying how two treatments—topical Ivermectin and oral Doxycycline—affect the skin and gut microbiome in people with rosacea compared to those without it. It uses DNA sequencing techniques to identify changes in microbial communities after treatment.
What are the potential side effects?
Possible side effects include skin irritation from Ivermectin and digestive upset from Doxycycline. Allergic reactions could occur for those sensitive to these drugs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am over 18 years old.
Select...
I can understand and communicate with my doctor.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I haven't used strong medications for skin issues recently.
Select...
I have a known bleeding disorder.
Select...
I am unable to understand and give consent for treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Difference in skin and gut microbiome between rosacea and control
Secondary study objectives
Change in skin and gut microbiome after 4-week of antimicrobial treatment in rosacea patients
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
6Treatment groups
Experimental Treatment
Active Control
Group I: Topical ivermectin(1%)Experimental Treatment1 Intervention
Topical ivermectin will be applied once a day for 28 days.
Group II: Doxycycline 50mg/dayExperimental Treatment1 Intervention
Doxycycline 50mg will be administered once a day per oral for 28 days.
Group III: Doxycycline 40mg/dayExperimental Treatment1 Intervention
Doxycycline 40mg will be administered once a day per oral for 28 days.
Group IV: Doxycycline 200mg/dayExperimental Treatment1 Intervention
Doxycycline 100mg will be administered twice a day per oral for 28 days.
Group V: Doxycycline 100mg/dayExperimental Treatment1 Intervention
Doxycycline 100mg will be administered once a day per oral for 28 days.
Group VI: ControlActive Control1 Intervention
No intervention will be performed.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Doxycycline
2008
Completed Phase 4
~2650
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Rosacea, particularly those involving antimicrobial therapy, work by targeting the altered skin and gut microbiota associated with the condition. Antibiotics such as tetracycline and metronidazole reduce inflammation and bacterial overgrowth, which can alleviate symptoms like redness, swelling, and pustules.
These treatments are crucial for Rosacea patients because they help restore a healthier balance of microbes, potentially reducing flare-ups and improving overall skin health.
Effect of combined systemic antimicrobial therapy and mechanical plaque control in patients with recurrent periodontal disease.Effect of the local probiotics in the therapy of periodontitis A randomized prospective study.An Insight into Acute Pericoronitis and the Need for an Evidence-Based Standard of Care.
Effect of combined systemic antimicrobial therapy and mechanical plaque control in patients with recurrent periodontal disease.Effect of the local probiotics in the therapy of periodontitis A randomized prospective study.An Insight into Acute Pericoronitis and the Need for an Evidence-Based Standard of Care.
Find a Location
Who is running the clinical trial?
Johns Hopkins UniversityLead Sponsor
2,316 Previous Clinical Trials
14,872,631 Total Patients Enrolled
1 Trials studying Rosacea
8 Patients Enrolled for Rosacea
Anna ChienPrincipal InvestigatorJohns Hopkins University
3 Previous Clinical Trials
21 Total Patients Enrolled
Media Library
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger